The SPIOMET4HEALTH Final Policy Event brought together researchers, clinicians, patient representatives and policymakers to discuss the future of Polyendocrine Metabolic Ovarian Syndrome (#PMOS) and the actions needed to translate research outcomes into real-world impact.
During the event, Christopher Mann from ASPHALION shared reflections on the regulatory and exploitation perspectives of the project, highlighting the importance of creating the right environment for innovative research to progress beyond clinical studies and ultimately benefit patients.
The discussions reinforced the value of collaboration across the scientific, regulatory and policy communities, as well as the need for sustained efforts to support innovation in women’s health.
One of the key messages highlighted during the event was clear: continued European Commission funding for clinical trials and programmes like SPIOMET is essential to generate the evidence needed to address unmet medical needs and ensure that promising research can continue its path towards patient benefit.
As SPIOMET4HEALTH approaches its conclusion, the project leaves behind not only important scientific evidence, but also valuable insights that can help shape future research, healthcare policies and therapeutic development in PMOS.
Need help for your Horizon Europe projects? Contact us at: [email protected]
